Harbour BioMed
和铂医药
Executive Summary
Harbour BioMed is a Suzhou-based biotech company with a differentiated H2L2 fully human antibody platform using transgenic mice technology. The company has demonstrated strategic partnership capability through its AbbVie collaboration on bispecific antibodies, indicating strong deal-making credentials. With clear BIOSECURE status and Hong Kong listing, it presents lower regulatory risk for US partnerships compared to mainland Chinese biotechs.
Structure: As a Hong Kong-listed entity (2142.HK), Harbour BioMed likely operates through a standard corporate structure rather than a VIE arrangement, which simplifies due diligence processes. The company appears to have consolidated operations in Suzhou with direct subsidiary control, reducing structural complexity typical of Chinese biotechs.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Jingsong Wang 王劲松 | Founder & CEO | PhD, Albert Einstein College of Medicine; Former head of antibody R&D at AbbVie |
Ownership & Shareholder Structure
Clinical Trials(17 total)
3
Phase 3
2
Phase 2
10
Phase 1
2
Phase 2, Phase 3
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05824663 | HBM1020 | Ph.1 | UNKNOWN | 50 |
| NCT05790694 | HBM9378 (SKB378) Injection, Placebo | Ph.1 | UNKNOWN | 50 |
| NCT05332210 | HBM9161 Injection (680mg) | Ph.3 | UNKNOWN | 144 |
| NCT05306444 | CLN-418 | Ph.1 | COMPLETED | 48 |
| NCT05167071 | HBM4003, Toripalimab, Tislelizumab | Ph.1 | ACTIVE NOT RECRUITING | 53 |
| NCT05149027 | HBM4003 and Triprilimab | Ph.1 | UNKNOWN | 67 |
| NCT05039190 | HBM9161 Injection (680mg), Placebo | Ph.3 | COMPLETED | 132 |
| NCT05015127 | HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7, Placebo | Ph.2, Ph.3 | UNKNOWN | 36 |
| NCT04866485 | HBM4003 and pembrolizumab | Ph.1 | UNKNOWN | 66 |
| NCT04727164 | HBM4003 and Triprilimab | Ph.1 | UNKNOWN | 61 |
| NCT04633213 | HBM9036 0.25% Ophthalmic Solution, Placebo | Ph.3 | UNKNOWN | 674 |
| NCT04346888 | HBM9161 Injection (680mg and 340 mg), Placebos, HBM9161 Injection (340 mg) | Ph.2 | COMPLETED | 30 |
| NCT04428255 | HBM9161 Dose A, HBM9161 Dose B, Placebo | Ph.2, Ph.3 | UNKNOWN | 36 |
| NCT04227470 | HBM9161 Injection | Ph.1 | COMPLETED | 9 |
| NCT04135261 | HBM4003 | Ph.1 | COMPLETED | 65 |
| NCT03971916 | HBM9161(HL161BKN), Placebo | Ph.1 | COMPLETED | 24 |
| NCT04092907 | HBM9036 0.25% Ophthalmic Solution, placebo | Ph.2 | COMPLETED | 100 |
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, and Hong Kong listing structure provides additional regulatory clarity
Key Exposures:
- •Suzhou operational base in mainland China
- •Potential future regulatory changes affecting all Chinese entities
Mitigation: Hong Kong listing structure and clear regulatory status provide natural insulation from BIOSECURE restrictions
BD Intelligence
Therapeutic Areas:
Recent Deals: Established strategic partnership with AbbVie for bispecific antibody development, demonstrating proven ability to execute complex international collaborations
Approach: Direct engagement with CEO Jingsong Wang recommended given his founder status and deal-making track record. Focus discussions on platform licensing opportunities and regional development partnerships.
Red Flags
- ⚠Limited recent corporate event visibility may indicate reduced business development activity
- ⚠Lack of subsidiary transparency could hide operational complexity
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 17
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (17 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.